OHSU Startup, NOUS Imaging, Receives 510(k) Clearance
OHSU Startup NOUS Imaging, a medical imaging software company, received 510(k) clearance from the FDA for FIRMM Software. Read more.

**CONGRATULATIONS!**

**To the 5 winners of the 2020 Catalyzing Pediatric Innovation (CPI) Grant!**

**CTIP Accelerator Announces 2020 Winners for Catalyzing Pediatric Innovation Annual Grant Competition**

The West Coast Consortium for Technology & Innovation in Pediatrics (CTIP), an FDA-funded MedTech accelerator to which OHSU is a network member, awarded seed grants on August 1, 2020 to push forward projects specifically designed to improve the safety and delivery of care to infants and children. Promedix, a company being formed based on OHSU technology, was one of five projects selected as winners for CTIP’s fourth Catalyzing Pediatric Grant (CPI) competition. The awarded grant will help develop Digital Capillary Refill, a product to improve the diagnostic accuracy of sepsis in children, with a goal to diagnose and treat pediatric sepsis earlier. Read more.

![Image](image-url)

**OBI & OTRADI Seeking Mentors and Mentees for January Cohort**

OBI is now accepting mentee applications for the mentor-mentee cohorts starting in January, 2021. Apply to become a mentee before October 31! Learn more.
Oregon Bio Digital 2020: Amplifying Diversity of Discovery, Access and Economics

Oregon Bio Digital 2020: Amplifying Diversity of Discovery, Access and Economics, held virtually on November 17, 18 and 19, offers local researchers and entrepreneurs a forum to share their exciting bioscience research and innovations. Planning is underway for three half-days of engaging panel discussions, networking, presentations and fun! Learn more.

Research and company pitches will be back. Pitch Applications are Open – Deadline extended to 10/7. Pitch Info and Application here.
A Virtual Event with its Heart in Portland October 23–25, 2020

OHSU is joining forces with MIT Hacking Medicine and more than 20 academic and industry partners for the inaugural OHSU Invent-a-thon, a virtual health care hackathon, **October 23–25, 2020.** Learn more and apply by October 14th.

3 Spots available for the Commercialization Design Studio November 11th

Increase your SBIR/STTR application's competitiveness with this proposal development resource. OHSU investigators receive free advice and feedback from a panel of SBIR/STTR experts on commercialization strategy and opportunity, research approach, feasibility assessment and overall readiness, among other critical review components.

Three one-hour slots are available and offered at no-cost to investigators by Collaborations and Entrepreneurship (C&E) and the Oregon Clinical and Translational Research Institute (OCTRI).

Contact Natalie Lovelace (lovelacn@ohsu.edu) to learn more and sign up to present.

TECHNOLOGIES AVAILABLE FOR LICENSING

**OHSU #2286** - A biomimetic mineralizing cell-culture medium
OHSU #2765 - Computer on Wheels Apparatus for better Interprofessional Communication

OHSU #2889 - CRISIS Ventilator

OHSU #2907 - Small molecule activates innate immune responses controlled by the human protein STING

NEWLY LICENSED OHSU TECHNOLOGIES

OHSU #1771 - Materials from the BioLibrary

OHSU #1238 - Compounds having antiparasitic or anti-infectious activity, Inventors: Michael Riscoe, Rolf Winter, Jane Kelly, David Hinrichs, Martin Smilkstein, Aaron Nilsen


U.S. PATENTS ISSUED

Patent #10,786,541 - Compositions and methods for treating heart disease and/or injury

Patent #10,760,097 - CMV glycoproteins and recombinant vectors

RESEARCHERS IN NEW INDUSTRY-FUNDED RESEARCH PROJECTS
**Markus Grompe** - Treatment of fatty liver with gene therapy (extended)

**Benjamin Burwitz** - Learning from the Ebola success: Can a mAb also save lives after yellow fever

**Phil Raess** - Bone Marrow Aspiration, Development and Clinical Study (extended)

**Daniel Streblow** - External Site Evaluation of RT-QPCR assay for SARS-CoV2 Infection

**John Brigande, Betsy Ferguson** - Phase I: Identification of Otoferlin Frameshift and Missence Mutants

**William Fleming** - Evaluate the functional activity of different human CD34 cell expansion platforms

### UPCOMING EVENTS

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>OCT 15-16</strong></td>
<td>Bend Venture Conference</td>
</tr>
<tr>
<td><strong>OCT 16</strong></td>
<td>Pitch Oregon: Application Deadline</td>
</tr>
<tr>
<td><strong>OCT 16-19</strong></td>
<td>Picture a Scientist: WIS Virtual Screening</td>
</tr>
<tr>
<td><strong>OCT 21</strong></td>
<td>Lunch and Learn: BIPOC imposter syndrome in STEM</td>
</tr>
<tr>
<td><strong>NOV 19</strong></td>
<td>OEN Entrepreneurship Award 2020</td>
</tr>
</tbody>
</table>
This message is being sent to X, X and X.